Medicus Pharma Ltd. Advances Non-Invasive Treatment for Basal Cell Carcinoma

Skin cancer, particularly basal cell carcinoma (BCC), affects millions annually in the U.S., with current treatments primarily surgical. Medicus Pharma Ltd. (NASDAQ:MDCX) is pioneering a non-invasive alternative through its subsidiary SkinJect Inc., utilizing a dissolvable microneedle patch to deliver chemotherapy directly to tumor cells, aiming to reduce pain, cost, and recovery time for patients.

Phase I trials have confirmed the safety and tolerability of the SkinJect patch, with Phase 2 studies underway. Early results show over 60% of participants achieving complete clinical clearance. The FDA has been approached for a fast-track approval, with studies expanding in the U.S., Europe, and the UAE. Additionally, Medicus is exploring veterinary applications for the technology, targeting equine squamous cell carcinoma.

The potential market for SkinJect is vast, with BCC procedures expected to reach 6 million by 2030. The treatment's estimated cost is significantly lower than current surgical options, offering substantial savings. Medicus's recent financial maneuvers, including a $7 million public offering and a planned acquisition of Antev Ltd., underscore its commitment to expanding its oncology portfolio and enhancing shareholder value.